Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus best supportive care versus placebo plus best supportive care in metastatic renal cell carcinoma after VEGF receptor tyrosine kinase inhibitor failure
2006-002070-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) comparing Everolimus plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: progression-free survival. Started Aug 2006; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2006-002070-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002070-21.